key: cord-0972061-lcynpqw2
authors: Muñoz, F. Longo; Salgado, A. Cortés; Domingo, J. J. Serrano; Casado, J. L.; Vallejo, A.; Serrano, C. Saavedra; Pérez, J. Chamorro; Rodríguez, D. I. Rosero; Velasco, H.; Martin, A.; Soria, A.; Garcia, M. E. Olmedo; Rueda, A. Gomez; Lage, Y.; Gordoa, T. Alonso; Cerrillo, J. Molina; Borau, P. Gajate; Martínez del Frade, Í.; Lopez, P. Garrido; Carrato-Mena, A.
title: 112P Immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in cancer patients receiving immunotherapy agents
date: 2021-12-31
journal: Annals of Oncology
DOI: 10.1016/j.annonc.2021.10.130
sha: 52364f2c58384b3c08b57b79e7705db2b3ce8729
doc_id: 972061
cord_uid: lcynpqw2

nan

(n¼161, 46.3%). Toxicity was the most common reason for dose hold (n¼94, 58.4%); 78 subsequently restarted AXI+PEM at their current (n¼19) or a reduced (n¼59) dose. Mean (SD) time to dose hold as first TM was 61.1 (55.9) days (n¼39, 11.2%). Toxicity was the reason for dose hold among 24 (61.5%) patients; of these, 23 restarted AXI+PEM at a reduced dose. Discontinuation was the first TM in 91 (26.2%) patients; mean (SD) time to discontinuation was 97.7 (89.7) days among them. Discontinuation was due to toxicity in 39 (42.9%) patients and progression in 29 (31.9%) patients; cabozantinib was the most common treatment (n¼31, 8.9%) after discontinuation.

Conclusions: Real world demographic and clinical characteristics were generally consistent with randomized controlled trials. Dose holds, changes and discontinuation were driven by toxicity; this analysis highlights opportunities to engage in targeted therapy management interventions to address treatment toxicity.

Editorial acknowledgement: Medical writing support was provided by Leon Adams, PhD, of Engage Scientific Solutions and funded by Pfizer.

Legal entity responsible for the study: Pfizer.

Funding: This study was sponsored by Pfizer. Background: Little is known about the influence of different anticancer therapies in the immunogenicity, efficacy, and safety of SARS-CoV-2 vaccines. Particularly, Immunotherapy could increase the rate of response to COVID-19 vaccines, counteracting cancer immunosuppression and restoring T-cell competence.

We conducted an observational study to assess the immunogenicity of mRNA-1273 SARS-CoV-2 vaccination in patients with solid tumours treated with immunotherapy. Blood samples were collected to analyse the humoral (specific antispike IgG) and cellular response (IFN-g producing CD4+ and CD8+ T-cells after stimulation with structural viral proteins) at baseline (BL), after the first vaccine dose (1D) and after the second vaccine dose (2D). Patients with previous COVID-19 or positive serology were excluded. Background: Immunotherapies targeting programmed death-1 and its ligand (PD-[L]1) revolutionized the therapeutic landscape in cancer. However, the rapidly growing number of patients eligible for these drugs challenges the affordability of health systems. This study aimed to estimate the health and budget impact of the anti-PD-(L) 1 class in Portugal and inform current discussions.

The study was based on the Health Impact Projection (HIP) model, which compares clinical outcomes (life years, progression-free survival [PFS] years, and patient quality-adjusted life years [QALY] gained and adverse events [AEs] occurred) and economic impact (direct and indirect costs) in a world where cancer patients are treated with standard-of-care (SOC; reference scenario) versus a mix of SOC and anti-PD-(L)1 (new scenario) in a 3-year time horizon (2021e2023). Six cancer types were included: adjuvant and metastatic melanoma, non-small cell lung cancer (first and second line), metastatic triple-negative breast cancer, head and neck cancer, urothelial carcinoma, and renal cell carcinoma. Model inputs were based on publicly available data, literature data, and expert opinion.

The model estimated that in 2021-2023, 12,890 patients would be diagnosed and treated with anti-PD-(L)1, realising a gain of 4,787 life years (+23% of relative gains), 6,901 PFS years (+98%), and 4,214 QALYs (+30%) and avoiding 399 AEs (+4%). The class had a projected average annual impact of z V108 million in the 3 years and a projected share of 20% of cancer care expenditure and 0.6% of total healthcare expenditure in 2021. Although higher disease management and administration costs are expected due to patients living longer with anti-PD-(L)1, and drug acquisition costs are considerable, some of it is offset by a reduction in end-of-life costs (average V611,092/year) and in costs of patient productivity lost to cancer (average V9,128,142/year).

Conclusions: This study highlights the clinical benefit of anti-PD-(L)1 for cancer patients and provides valuable insights to policymakers on their economic impact on cancer care costs and healthcare system budget, contributing to decision-making and budget planning. 

Invited Speaker: Amgen; Financial Interests, Personal, Advisory Board: Amgen

Invited Speaker: Astellas; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Invited Speaker: Bayer; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Invited Speaker: BBraun; Financial Interests, Personal, Advisory Board: BBraun; Financial Interests, Personal

Personal, Invited Speaker: Janssen; Financial Interests, Personal, Advisory Board: Janssen; Financial Interests, Personal, Invited Speaker: Merck-Serono; Financial Interests

Teixeira Sousa: Financial Interests, Personal, Invited Speaker: Roche; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Invited Speaker: Merck Sharp & Dohme; Financial Interests, Personal, Advisory Board: Merck Sharp & Dohme; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Invited Speaker: Pierre-Fabre; Financial Interests, Personal, Advisory Board: Pierre-Fabre; Financial Interests, Personal, Invited Speaker: Bristol-Myers Squibb; Financial Interests, Personal, Advisory Board: Bristol-Myers Squibb; Financial Interests, Personal

Invited Speaker: Lilly; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Invited Speaker: Pfizer; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Invited Speaker: Tesaro; Financial Interests, Personal, Advisory Board: Tesaro. C.M. Pereira Vieira: Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Bristol-Myers Squibb; Financial Interests

Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Grünenthal. E. Bell: Financial Interests, Personal, Full or part-time Employment: Adelphi Values Ltd. O. Swales: Financial Interests, Personal, Full or part-time Employment: Adelphi Values Ltd. R. Hughes: Financial Interests, Personal, Full or part-time Employment: Adelphi Values Ltd. N. Nagda: Financial Interests, Personal, Full or part-time Employment: Adelphi Values Ltd. S. Lucherini: Financial Interests, Personal, Full or part-time Employment: Adelphi Values Ltd. A. Roediger: Financial Interests